OBSOLETE: Bacterial susceptibility due to TLR signaling pathway deficiency

Bacterial susceptibility due to TLR (Toll-like receptor) signaling pathway deficiency is an obsolete Orphanet classification (ORPHA:183713) that previously grouped a set of primary immunodeficiency disorders characterized by increased vulnerability to specific bacterial infections resulting from defects in the innate immune system's TLR signaling cascade. TLR signaling is a critical component of innate immunity, responsible for recognizing pathogen-associated molecular patterns and initiating inflammatory and antimicrobial responses. Deficiencies in this pathway — including defects in genes such as IRAK4, MYD88, and others involved in TLR signal transduction — lead to impaired production of pro-inflammatory cytokines and inadequate early immune responses against pyogenic (pus-forming) bacteria, particularly invasive pneumococcal disease, staphylococcal infections, and other Gram-positive bacterial infections. This grouping has been rendered obsolete because the individual conditions within it are now classified separately under more specific diagnostic entities, such as IRAK-4 deficiency (ORPHA:70592) and MyD88 deficiency (ORPHA:183713 subentities). Patients with these conditions typically present in infancy or early childhood with recurrent, severe, and sometimes life-threatening bacterial infections, including meningitis, sepsis, arthritis, and deep-seated abscesses. Notably, susceptibility to viral and fungal infections is generally not significantly increased. The immune system's adaptive arm remains largely intact. Treatment primarily involves long-term prophylactic antibiotics, aggressive treatment of acute infections, and in some cases immunoglobulin replacement therapy. Vaccination against encapsulated bacteria (e.g., pneumococcus) is recommended, though vaccine responses may be suboptimal. With age, the frequency and severity of infections tend to decrease, possibly due to maturation of adaptive immune responses.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about OBSOLETE: Bacterial susceptibility due to TLR signaling pathway deficiency